文献速递肝病消化道肿瘤与早癌

血清细胞外囊泡含有用于原发性硬化性胆管炎和胆管癌的蛋白质生物标志物

Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.
PubMed 文献 · Hepatology · 2017-08-26

研究从胆管癌(n=43)、原发性硬化性胆管炎(n=30)、肝细胞癌(n=29)患者及健康对照(n=32)血清中分离细胞外囊泡并分析蛋白质组,发现组间多个差异表达蛋白,部分蛋白诊断价值较高,最高曲线下面积达0.956(I-II期胆管癌 vs 原发性硬化性胆管炎)。

要点

  • 肝细胞癌组血清细胞外囊泡浓度高于所有其他组。
  • 多个差异蛋白诊断曲线下面积最高达0.878(胆管癌 vs 对照)和0.956(I-II期胆管癌 vs 原发性硬化性胆管炎)。
  • 胆管癌细胞来源细胞外囊泡中致癌蛋白丰度高于正常胆管细胞来源者。

核心结论

  • 胆管癌、原发性硬化性胆管炎和肝细胞癌患者血清细胞外囊泡的蛋白质组特征显示出作为诊断工具的潜在用途。

研究设计与样本

  • 从胆管癌(n=43)、原发性硬化性胆管炎(n=30)、肝细胞癌(n=29)患者及健康个体(对照,n=32)血清中分离细胞外囊泡并表征其蛋白质含量。

主要发现

  • 纳米颗粒跟踪分析显示肝细胞癌组血清细胞外囊泡浓度高于所有其他组。
  • 透射电镜显示圆形形态、纳米颗粒跟踪分析显示直径约180 nm、免疫印迹显示分化簇9、63和81标记物,表明大多数血清细胞外囊泡为外泌体。
  • 质谱蛋白质组谱揭示组间多个差异表达蛋白,部分蛋白诊断价值较高,最大曲线下面积:胆管癌 vs 对照0.878,I-II期胆管癌 vs 对照0.905,原发性硬化性胆管炎 vs 对照0.789,非肝硬化原发性硬化性胆管炎 vs 对照0.806,胆管癌 vs 原发性硬化性胆管炎0.796,I-II期胆管癌 vs 原发性硬化性胆管炎0.956,肝细胞癌 vs 对照0.904,肝内胆管癌 vs 肝细胞癌0.894。
  • 体外胆管癌人类细胞来源细胞外囊泡的蛋白质组分析显示致癌蛋白丰度高于正常人类胆管细胞释放的细胞外囊泡。
  • 免疫缺陷小鼠肝脏原位植入胆管癌人类细胞后,血清中释放的细胞外囊泡含有一些类似的人类致癌蛋白。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Cholangiocarcinoma (CCA) includes a heterogeneous group of biliary cancers with poor prognosis. Several conditions, such as primary sclerosing cholangitis (PSC), are risk factors. Noninvasive differential diagnosis between intrahepatic CCA and hepatocellular carcinoma (HCC) is sometimes difficult. Accurate noninvasive biomarkers for PSC, CCA, and HCC are not available. In the search for novel biomarkers, serum extracellular vesicles (EV) were isolated from CCA (n = 43), PSC (n = 30), or HCC (n = 29) patients and healthy individuals (control, n = 32); and their protein content was characterized. By using nanoparticle tracking analysis, serum EV concentration was found to be higher in HCC than in all the other groups. Round morphology (by transmission electron microscopy), size (∼180 nm diameter by nanoparticle tracking analysis), and markers (clusters of differentiation 9, 63, and 81 by immunoblot) indicated that most serum EV were exosomes. Proteome profiles (by mass spectrometry) revealed multiple differentially expressed proteins among groups. Several of these proteins showed high diagnostic values with maximum area under the receiver operating characteristic curve of 0.878 for CCA versus control, 0.905 for CCA stage I-II versus control, 0.789 for PSC versus control, 0.806 for noncirhottic PSC versus control, 0.796 for CCA versus PSC, 0.956 for CCA stage I-II versus PSC, 0.904 for HCC versus control, and 0.894 for intrahepatic CCA versus HCC. Proteomic analysis of EV derived from CCA human cells in vitro revealed higher abundance of oncogenic proteins compared to EV released by normal human cholangiocytes. Orthotopic implant of CCA human cells in the liver of immunodeficient mice resulted in the release to serum of EV containing some similar human oncogenic proteins. CONCLUSION: Proteomic signatures found in serum EV of CCA, PSC, and HCC patients show potential usefulness as diagnostic tools. (Hepatology 2017;66:1125-1143).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Arbelaiz A, Azkargorta M, Krawczyk M, et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2017. PMID: 28555885. doi:10.1002/hep.29291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。